November 28, 2023

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating expenses of approximately $60 million, including a reduction in headcount of approximately 200 colleagues, 13% of total workforce ROOT, Switzerland–(BUSINESS… Read More
learn more
November 21, 2023

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 3:30 p.m. EST, as… Read More
learn more
November 10, 2023

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for… Read More
learn more
October 26, 2023

Novocure Reports Third Quarter 2023 Financial Results

Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of… Read More
learn more
October 15, 2023

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Highlights include a new analysis showing that Tumor Treating Fields therapy, when added to standard systemic therapies, did not adversely affect patients’ quality of life in the phase 3 LUNAR clinical trial. ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced its participation in the European Society for… Read More
learn more
October 12, 2023

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical… Read More
learn more
October 2, 2023

Novocure to Report Third Quarter 2023 Financial Results

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and… Read More
learn more
September 29, 2023

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about… Read More
learn more
September 8, 2023

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC)… Read More
learn more
August 29, 2023

Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy… Read More
learn more